Sedative & Hypnotic Drugs II
      Brian J. Piper, Ph.D., M.S.




                     January 23, 2013
Goals
• Sleep Neurochemistry
• Hypnotic Pharmacy
  – benzodiazepines
  – “Z” drugs
  – melatonin agonists
Sleep Across the Lifespan




Roffwarg, Muzio, & Dement (1966). Science, 152(3722), 604-619.
Insomnia Disorder
Epidemiology of Insomnia
    Sex: 2 F: 1 M
    5% of adults
    Age: 50% of elderly
    Other conditions:
          smoking or drinking
          anxious or depressed
          chronic pain

Ohayon (2002) Sleep Medicine Reviews, 67(2), 97-111.
Neurobiology
          of Sleep
• Hypothalamus
  – Suprachiasmatic Nucleus (SCN): pacemaker
• Pineal Gland (Melatonin)
• Reticular Formation (5-HT, DA, NE, ACh)
Arousal Spectrum




Stahl (2008). Essential Psychopharmacology, p. 817.
Perfect Hypnotic
• On/Off
• Non-habit forming
Stahl (2008). Essential Psychopharmacology, p. 840.
Stahl (2008). Essential Psychopharmacology, p. 835.
Half-Life ≈ 6 hours




Stahl (2008). Essential Psychopharmacology, p. 841.
FDA Approved
                                                      For Insomnia (t1/2)
                                                      Estazolam (17)
                                                      Flurazepam (70)
                                                      Quazepam (39)
                                                      Temazepam (25)
                                                      Triazolam (2)




Stahl (2008). Essential Psychopharmacology, p. 841.
Benzodiazepine Dependence




Stahl (2008). Essential Psychopharmacology, p. 841.
“Z Drugs”
     •   Examples: zolpidem, zaleplon
     •   MOA: α1 GABAA POM
     •   Indications: insomnia
     •   Adverse Events
          – Allergic reaction
          – Automatic behaviors (non-remembered)




Min 1 to 3: http://www.youtube.com/watch?v=FDK1TAkmHjs
Daley et al. (2011). Journal of the American Academy of Psychiatry & the Law, 39, 535-542.
Idealized (?)




Stahl (2008). Essential Psychopharmacology, p. 838.
Benzo versus “Z drug”
    • Insomniacs were randomized to receive 28
      days of zolpidem (10 mg/day, N = 79) or
      temazepam (20 mg/day, N = 84). Double-blind
    • Sleep diaries were completed for 1 week post-
      hypnotics
                                                temazepam zolpidem
                           ↓ total sleep time
                           (40%+)
                                                26%                 27%
                           ↑ sleep onset
                           latency (40%+)
                                                58%                 53%


Voshaar et al. (2004). European Neuropsychopharmacology, 14, 301-306.
Modified from Stahl (2008). Essential Psychopharmacology, p. 838.
Melatonin Rhythm




Reiter, R. J. (1995). Experimental Gerontology, 30(3/4), 199-212.
Ramelteon
    •   MOA: Melatonin (M12) agonist
    •   Indication: insomnia (sleep onset)
    •   Half-life: 2 hours
    •   Adverse effects: limited
    •   Schedule: not controlled




Bonus (3 min): http://www.youtube.com/watch?v=rIpjfTbCHJ8
Summary
             Benzo               Z drug             Melatonin Agonist
             Diazepam            Zolpidem           Ramelteon

MOA          GABAA α1,2,3,5      GABAA α1           M1,2
Year         1963                1986               2005
Developed
Indication   Insomnia (onset &   Insomnia (onset)   Insomnia (onset)
             maintenance)                           Long-term
Half-Life    50                  3                  2
(hours)
Withdrawal   Yes                 Yes?               No
Issues
Stahl (2008). Essential Psychopharmacology, p. 819.
Self-Test #1
• Patient C.D. appears to have over-dosed on
  Zolpidem. What agent would be appropriate
  in this situation?
  – A) zaleplon (Sonata)
  – B) flumazenil (Romazicon)
  – C) pentobarbital (Nembutal)
  – D) ramelteon (Rozerem)
  – E) eszopiclone (Lunesta)

Sedative & Hypnotic Drugs Part II

  • 1.
    Sedative & HypnoticDrugs II Brian J. Piper, Ph.D., M.S. January 23, 2013
  • 2.
    Goals • Sleep Neurochemistry •Hypnotic Pharmacy – benzodiazepines – “Z” drugs – melatonin agonists
  • 3.
    Sleep Across theLifespan Roffwarg, Muzio, & Dement (1966). Science, 152(3722), 604-619.
  • 4.
  • 5.
    Epidemiology of Insomnia Sex: 2 F: 1 M 5% of adults Age: 50% of elderly Other conditions: smoking or drinking anxious or depressed chronic pain Ohayon (2002) Sleep Medicine Reviews, 67(2), 97-111.
  • 6.
    Neurobiology of Sleep • Hypothalamus – Suprachiasmatic Nucleus (SCN): pacemaker • Pineal Gland (Melatonin) • Reticular Formation (5-HT, DA, NE, ACh)
  • 7.
    Arousal Spectrum Stahl (2008).Essential Psychopharmacology, p. 817.
  • 8.
  • 9.
    Stahl (2008). EssentialPsychopharmacology, p. 840.
  • 10.
    Stahl (2008). EssentialPsychopharmacology, p. 835.
  • 11.
    Half-Life ≈ 6hours Stahl (2008). Essential Psychopharmacology, p. 841.
  • 12.
    FDA Approved For Insomnia (t1/2) Estazolam (17) Flurazepam (70) Quazepam (39) Temazepam (25) Triazolam (2) Stahl (2008). Essential Psychopharmacology, p. 841.
  • 13.
    Benzodiazepine Dependence Stahl (2008).Essential Psychopharmacology, p. 841.
  • 14.
    “Z Drugs” • Examples: zolpidem, zaleplon • MOA: α1 GABAA POM • Indications: insomnia • Adverse Events – Allergic reaction – Automatic behaviors (non-remembered) Min 1 to 3: http://www.youtube.com/watch?v=FDK1TAkmHjs Daley et al. (2011). Journal of the American Academy of Psychiatry & the Law, 39, 535-542.
  • 15.
    Idealized (?) Stahl (2008).Essential Psychopharmacology, p. 838.
  • 16.
    Benzo versus “Zdrug” • Insomniacs were randomized to receive 28 days of zolpidem (10 mg/day, N = 79) or temazepam (20 mg/day, N = 84). Double-blind • Sleep diaries were completed for 1 week post- hypnotics temazepam zolpidem ↓ total sleep time (40%+) 26% 27% ↑ sleep onset latency (40%+) 58% 53% Voshaar et al. (2004). European Neuropsychopharmacology, 14, 301-306.
  • 17.
    Modified from Stahl(2008). Essential Psychopharmacology, p. 838.
  • 18.
    Melatonin Rhythm Reiter, R.J. (1995). Experimental Gerontology, 30(3/4), 199-212.
  • 19.
    Ramelteon • MOA: Melatonin (M12) agonist • Indication: insomnia (sleep onset) • Half-life: 2 hours • Adverse effects: limited • Schedule: not controlled Bonus (3 min): http://www.youtube.com/watch?v=rIpjfTbCHJ8
  • 20.
    Summary Benzo Z drug Melatonin Agonist Diazepam Zolpidem Ramelteon MOA GABAA α1,2,3,5 GABAA α1 M1,2 Year 1963 1986 2005 Developed Indication Insomnia (onset & Insomnia (onset) Insomnia (onset) maintenance) Long-term Half-Life 50 3 2 (hours) Withdrawal Yes Yes? No Issues
  • 22.
    Stahl (2008). EssentialPsychopharmacology, p. 819.
  • 23.
    Self-Test #1 • PatientC.D. appears to have over-dosed on Zolpidem. What agent would be appropriate in this situation? – A) zaleplon (Sonata) – B) flumazenil (Romazicon) – C) pentobarbital (Nembutal) – D) ramelteon (Rozerem) – E) eszopiclone (Lunesta)

Editor's Notes

  • #6 Other factors: marital status (higher for divorced) and lower income have been less consistently observed.
  • #7 The term "reticulum" means "netlike structure," which is what the reticular formation resembles at first glance. RF includes raphe and locus coeruleus and projects to thalamus.
  • #10 Half-life< 3 hours is too short.
  • #11 A half-life of 15-30 hours is too long (e.g. estazolam or ProSom).
  • #13 Half-lifes includes half-life of major metabolites and are from Katzung.
  • #14 Do a search for benzodiazepine addiction in youtube for videos of people ranting about their benzo experience.
  • #15 Complex automatic behaviors occur in 1-5% of patients.
  • #17 Rebound insomnia (compared to placebo baseline) does not differ between these agents. Interestingly, this study was funded by the manufacturer of zolpidem (Sanofi-Synthelab).
  • #20 Adverse reactions from PDR.net include dizziness, somnolence, fatigue, nausea, and exacerbated insomnia.
  • #23 Excessive stimulants (amphetamine) can go beyond arousal and result in hallucinations.